These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30198061)

  • 1. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
    Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
    Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
    Danzon PM
    Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Price Models for Multi-indication Drugs: A Systematic Review.
    Campillo-Artero C; Puig-Junoy J; Segú-Tolsa JL; Trapero-Bertran M
    Appl Health Econ Health Policy; 2020 Feb; 18(1):47-56. PubMed ID: 31523756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of studies reporting actual prices for medicines.
    Mardetko N; Kos M; Vogler S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indication-specific Drug Pricing - Simple in Theory, Complex in Reality.
    Kwon S
    Manag Care; 2018 May; 27(5):23-25. PubMed ID: 29763404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical reference prices. How do they work in practice?
    Dickson M; Redwood H
    Pharmacoeconomics; 1998 Nov; 14(5):471-9. PubMed ID: 10344913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
    Ha SY; Kang DW; Jung HI; Lee EK; Park MH
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
    Moodley R; Suleman F
    BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review.
    Preckler V; Espín J
    Value Health; 2022 Apr; 25(4):666-675. PubMed ID: 35227598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new approach to pharmaceutical pricing based on patients' willingness to pay.
    Rahimi F; Rasekh HR; Abbasian E; Peiravian F
    Trop Med Int Health; 2018 Dec; 23(12):1326-1331. PubMed ID: 30286256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
    Carapinha JL
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):11-4. PubMed ID: 26707161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.